<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-108630</identifier>
<setSpec>2174-5544</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Inhibin A in second trimester screening of Down's syndrome</dc:title>
<dc:description xml:lang="en">Objective. To evaluate the efficacy of inhibin A in second trimester screening of Down's syndrome in terms of detection rate and percentage of positive results. Methods. A retrospective study of 3380 pregnant women who underwent second trimester screening, classified into 2 groups, one which included inhibin A (1921 pregnant women) and one that did not (1459 pregnant women). Results. The detection rate (cut-off: 1:250) was 90% in the group with inhibin A and 84.6% in the other group, but the percentage of positive results was significantly lower in the first group (11% vs. 15.9%, P&lt;.001). The results were similar if we compared the positive likelihood ratio between groups (8.47 vs. 5.54, P&lt;.001). Conclusion. Inhibin A is a useful marker in second trimester screening due to the low percentage of positive cases observed, thereby reducing the number of amniocentesis(AU)</dc:description>
<dc:creator>Casals, Elena</dc:creator>
<dc:creator>Casamitjana, Roser</dc:creator>
<dc:creator>Escudero Fernández, José Miguel</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo. Comprobar la eficacia de la incorporación de la inhibina A en el cribado de segundo trimestre del síndrome de Down en términos de tasa de detección y porcentaje de cribados positivos. Métodos. Estudio retrospectivo de 3.380 embarazadas, que se sometieron al cribado de segundo trimestre, clasificadas en 2 grupos en función de la incorporación de la inhibina A (1.921 mujeres) o no (1.459 mujeres).Resultados. La tasa de detección con un punto de corte de 1:250 fue del 90% en el grupo de inhibina A y 84,6% sin inhibina A, pero con un porcentaje de cribados positivos significativamente menor en el primero (11 vs. 15,9%; p &lt; 0,001). Este concepto también se refleja al comparar el likelihood ratio positivo entre ambos grupos (8,47 vs. 5,54; p &lt;0,001). Conclusión. Es aconsejable la incorporación de la inhibina A en el cribado de segundo trimestre, ya que se observa un menor porcentaje de casos positivos, con la consiguiente reducción en el número de amniocentesis a realizar(AU)</dc:description>
<dc:source>Diagn. prenat. (Internet);22(4): 113-116, oct.-dic. 2011.</dc:source>
<dc:identifier>ibc-108630</dc:identifier>
<dc:title xml:lang="es">Utilidad de la inhibina A en el cribado de síndrome de Down en el segundo trimestre</dc:title>
<dc:subject>^d22261</dc:subject>
<dc:subject>^d25123^s22045</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d664^s22039</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d664^s22074</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d7440^s22073</dc:subject>
<dc:subject>^d664^s22045</dc:subject>
<dc:subject>^d30934^s22016</dc:subject>
<dc:subject>^d11704^s22038</dc:subject>
<dc:subject>^d664^s22066</dc:subject>
<dc:subject>^d30934^s22012</dc:subject>
<dc:subject>^d11704^s22031</dc:subject>
<dc:subject>^d11704^s22044</dc:subject>
<dc:subject>^d53386</dc:subject>
<dc:type>article</dc:type>
<dc:date>201112</dc:date>
</metadata>
</record>
</ibecs-document>
